CRB-913 - (CANYON-1)

August 6, 2026: Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) reported a corporate update highlighting two upcoming clinical catalysts. For CRB-701, a Nectin-4-targeting ADC for oropharyngeal squamous cell carcinoma (OPSCC) and cervical cancer, the company said the FDA cleared the registrational TEMPO-1 study in second-line OPSCC; the Phase 3 trial is planned to enroll 250 patients, with enrollment expected to begin in September 2026. Corbus also said it previously presented Phase 1/2 second-line-plus monotherapy data in head and neck squamous cell carcinoma and cervical cancer at the 2026 ASCO Annual Meeting, and expects CRB-701 plus Keytruda combination data in first-line OPSCC in Q1 2027 to support potential additional registration-enabling trials.

For CRB-913, an oral peripherally restricted CB1 inverse agonist for obesity, Corbus said the last patient completed the last visit in the CANYON-1 Phase 1b study. The trial enrolled 240 patients, with 12 weeks of treatment plus 4 weeks of safety follow-up; topline data remain on track for September 2026.

The company also announced appointments of a new Chief Medical Officer, Chief Business Officer, and board member. Cash, cash equivalents, and investments were $117.9 million as of June 30, 2026, which the company said should fund operations into 2028.